Applied Biosystems, a division of Life Technologies Corporation, and its mass spectrometry joint-venture partner, MDS Analytical Technologies, a business unit of MDS Inc., launched Cliquid MPX-2 high-throughput workflow, an end-to-end solution for mass spectrometry users to accelerate productivity for pharmaceutical and clinical research. The Cliquid MPX workflow integrates a new software application with mass spectrometers, high-performance liquid chromatography systems and auto-samplers to uniquely increase throughput for faster results while in accordance with Good Laboratory Practice (GLP) standards of regulated markets. This can help bring new drugs to market more quickly.
The new Cliquid MPX solution addresses the need of pharmaceutical companies and clinical researchers to improve the productivity and efficiency of laboratory analysis. This solution can as much as double the throughput of Applied Biosystems/MDS Analytical Technologies QTRAP and triple quadrupole mass spectrometers, which are widely used to analyze high volumes of samples. This increased speed enables scientists to more rapidly collect critical data that affects decision-making for advancing a drug candidate or conducting clinical studies.
The workflow is enabled by Cliquid MPX software, which allows concurrent LC/MS/MS analysis of two streams into a single mass spectrometer with either Cliquid Software or Analyst Software. This is an innovation in mass spectrometry to create a single point of control for managing the complete workflow, which is supported by Applied Biosystems Global Services. This enables laboratories to increase throughput while achieving regulatory compliance by using the audit and traceability functionality of Analyst Software, providing the most efficient solution of its type within the life-science industry.
Filed Under: Drug Discovery
